drugset / Trial / NCT05906706

Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid

NCT05906706

Expanded access Approved for marketing Regeneron Pharmaceuticals Sanofi · collab

Summary

The objective of the program is to provide patients with Bullous Pemphigoid (BP), that participated in the R668-BP-1902 (NCT04206553) phase 2/3 study, dupilumab treatment and evaluate the long-term safety of dupilumab.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody Subcutaneous

Indications